STIMIT's CEO Ronja Bruhn on How to Help Accelerate COVID-19 Patient Recovery
29.03.2020
STIMIT's CEO and co-founder Ronja Bruhn is telling us about their therapy and medical device to empower patients in intensive care to breathe, such as the numerous ones suffering from the effects of COVID-19. STIMIT's technologies can non-invasively activate the body's own breathing function.
 |
 |
What are STIMIT's mission and core innovation?
STIMIT's therapy goal is to maintain breathing muscle function during ventilation, to minimize life-threatening damage to the lungs from mechanical ventilation, and shorten the duration of ventilation for intensive care patients.
How will the CHF 150’000.- investment from Venture Kick help achieve your vision?
Venture Kick’s additional funding comes at the right time and is a relevant building block to further accelerate our therapy developments - empowering patients to breathe. Our goal is to improve outcomes in ventilated patients and help intensive care units to treat more patients in less time.
How did Venture Kick help you lay the foundation for your growth and today's achievement?
Venture Kick accelerated STIMIT build an attractive investor package. We travelled around Europe and the USA to build relationships with key opinion leaders that are excited about our innovation and waiting now to use our first product in their clinics
When will you be able to help accelerate patient recovery in this period of COVID-19?
We have developed our first functional design, and are now preparing ourselves to build therapeutic clinical evidence in the next months to help ventilated intensive care patients recover faster; STIMIT and partners are in close contact with notified bodies from EU and the USA ensuring not to lose time in making our medical device available for patients around the world.